Fig. 4

Galantamine controls splenomegaly in vagotomized (VGX) and α7nAChR knocked-out FMF-KI (FMF/α7-KO) mice. A Spleen weights (mg) from galantamine- and PBS-treated vagotomized mice after ~ 4 weeks of treatment. B Spleen area (Width x Length cm²) before abdominal VGX (measured intra-operatively during VGX procedure) compared to area after 4 weeks of galantamine or PBS treatment. C Spleen sizes (mg) from galantamine- and PBS-treated α7nAChR deficient FMF-KI mice after 4–6 weeks of treatment with galantamine (escalated to 12 mg/kg twice daily) starting at age ~ 4–5 weeks (treated n = 5; control n = 4). Spleen weights (mg) from α7-intact mice at ~ 9–10 weeks of age (historical) are included for comparison only. Data presented as mean ± SEM; *P < 0.05 by Mann–Whitney U test